Tesamorelin — Peptide Dosing Protocols reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
Tesamorelin Peptide Guide: Benefits, Dosing & FDA Status (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Tesamorelin Peptide Guide: Dosing, Reconstitution & Safety Protocol / Research Dosing Guide Tesamorelin Peptide Guide: Dosing, Reconstitution & Safety Tesamorelin is the only FDA-approved GHRH peptide. This guide covers dosing for Egrifta SV, Egrifta WR, and research vials, plus reconstitution math, supplies, side effects, and Phase III trial data. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Tesamorelin Vials View Supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Tesamorelin Comparisons Related Protocols Blood Tests FAQ References Tesamorelin Quick Start Tesamorelin is the only FDA-approved GHRH (growth hormone-releasing hormone) peptide .
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (9) · phenotypes (0)
evidence_reference, dosing_reference, mechanism, safety_reference, contraindication_reference, monitoring_reference
Findings (198) · awaiting review (141)
dosing · pending
8 weeks 12 vials (10 mg) 56 daily doses needed.
dosing · pending
12 weeks 17 vials (10 mg) 84 daily doses needed.
regulatory · pending
Use for any other purpose is off-label and should involve a licensed clinician.
regulatory · pending
All other use is off-label.
regulatory · pending
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy.
dosing · pending
osing by Formulation Choose the formulation you are researching to see the matching daily dose and prep notes.
dosing · pending
Tesamorelin Peptide Guide: Benefits, Dosing & FDA Status (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Tesamorelin Peptide Guide: Dosing, Reconstitution & Safety Protocol / Research Dosing Guide Tesamorelin Peptide Guide: Dosing, Reconstitution & Safety Tesamorelin is the only FDA-approved GHRH peptide.
dosing · pending
This guide covers dosing for Egrifta SV, Egrifta WR, and research vials, plus reconstitution math, supplies, side effects, and Phase III trial data.
dosing · pending
By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Tesamorelin Vials View Supply Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Dosage Chart Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Tesamorelin Comparisons Related Protocols Blood Tests FAQ References Tesamorelin Quick Start Tesamorelin is the only FDA-approved GHRH (growth hormone-releasing hormone) peptide .
mechanism · pending
It signals your pituitary gland to release more of your own growth hormone in its natural rhythm.
regulatory · pending
It is also sold as research-grade vials for off-label study.
dosing · pending
Most protocols use 2 mg once a day under the skin of the abdomen.
dosing · pending
1.4 mg daily and Egrifta WR uses 1.28 mg daily.
dosing · pending
Research vials usually come in 2 mg, 5 mg, or 10 mg sizes and are mixed with bacteriostatic water before use.
dosing · pending
Route Subcutaneous injection in the abdomen only.
dosing · pending
Schedule Once daily.
dosing · pending
Full dose from day one.
regulatory · pending
Research status FDA-approved for HIV lipodystrophy.
dosing · pending
This page covers Tesamorelin dose steps, timing, vial math, and storage.
safety · pending
It covers how it works, study results, side effects, and legal status.
dosing · pending
Tesamorelin Dosing Protocol & Schedule Unlike most peptides, tesamorelin does not need a slow ramp-up.
dosing · pending
The FDA label starts patients at the full dose on day one.
dosing · pending
The table below shows dosing for all three formulations: Egrifta SV (the current main product), Egrifta WR (a newer once-weekly-reconstitution version), and legacy Egrifta (the original 2 mg/day product used in trials).
dosing · pending
Research vials from grey-market sources are usually dosed like legacy Egrifta — 2 mg once a day .
dosing · pending
Research Vials (2/5/10 mg) Egrifta SV Egrifta WR Grey-market research-grade vials.
dosing · pending
Research-grade vials are usually 2 mg, 5 mg, or 10 mg of lyophilized (freeze-dried) powder.
dosing · pending
Most protocols match the original Phase III dose: 2 mg per day , given as one subcutaneous injection in the abdomen.
dosing · pending
Research Vial Dosing — Phase III Equivalent Phase Day 1 onward Timing Every day Daily Dose 2 mg Notes No titration.
dosing · pending
Phase Weeks 1-26 Timing Daily Daily Dose 2 mg Notes Phase III trial exposure pattern.
dosing · pending
Phase Continued therapy Timing Daily Daily Dose 2 mg Notes Trials showed effects reverse when stopped.
dosing · pending
Phase Timing Daily Dose Notes Day 1 onward Every day 2 mg No titration.
dosing · pending
Weeks 1-26 Daily 2 mg Phase III trial exposure pattern.
dosing · pending
Continued therapy Daily 2 mg Trials showed effects reverse when stopped.
dosing · pending
Research-vial dosing mirrors the original 2 mg/day legacy Egrifta protocol used in LIPO-010 and CTR-1011.
regulatory · pending
Current FDA product with smaller daily volume.
regulatory · pending
Egrifta SV is the current FDA-approved version of tesamorelin.
dosing · pending
Each 2 mg vial is mixed with 0.5 mL of supplied diluent.
dosing · pending
After reconstitution, the daily dose is 1.4 mg , drawn as 0.35 mL , injected once a day under the skin of the abdomen
dosing · pending
Egrifta SV — Label Dosing Phase Day 1 onward Timing Every day Daily Dose 1.4 mg Notes Draw 0.35 mL after reconstitution with 0.5 mL diluent.
dosing · pending
Phase Maintenance Timing Daily Daily Dose 1.4 mg Notes Use immediately after mixing (per label).
Processing
Processed into 28 searchable sections.